Education

Demystifying specialty drug pricing acronyms, and why they all fail employers

aVsOVXNYClf9oxMj Leap Acronyms image

Behind the exorbitant costs of infusion therapies, you’ll find layers of complexity—and three acronyms that confuse more than they clarify: ASP, AWP, and WAC. Here’s what they mean, who uses them, and why they’re all part of a broken system that drives up costs.

What’s the difference?

Let’s break them down one at a time:

  • Average Wholesale Price (AWP): Despite its name, AWP isn’t what anyone actually pays. It’s a benchmark price set by drug manufacturers that often reflects a 20–25% markup over what providers pay. AWP is still commonly used by insurers and pharmacy benefit managers as a reference point, but its inflated nature makes it a poor proxy for actual costs.
  • Wholesale Acquisition Cost (WAC): WAC is the price a wholesaler pays to the manufacturer for a drug, not including discounts or rebates. It’s closer to a "list price" and is used for cataloging and forecasting. Like AWP, it often bears little resemblance to the true transactional price after all the deals are done.
  • Average Sales Price (ASP): ASP attempts to reflect the real-world average price, including discounts and rebates. It’s calculated by the Centers for Medicare & Medicaid Services for Part B drugs and is often used in public reimbursement models. But ASP lags in time and doesn’t account for commercial market dynamics or the full impact of administrative markups.

Why should employers care?

Because none of these models reflect what they actually pay.

When a provider purchases a drug under the traditional buy-and-bill model, they buy the drug (often at or below WAC), administer it, then bill the plan based on AWP or ASP plus a markup. In a hospital outpatient department, that markup can reach 500%. Even in an ambulatory infusion center, you’re still looking at 50% markups or more.

The result? Employers end up paying dramatically different prices for the same drug depending on where and how it’s administered, not what it’s worth.

Why the system is failing employers

  • No consistency: Pricing is opaque and varies wildly across settings.
  • No control: Employers are locked into contracts they can’t negotiate.
  • No value: Inflated markups aren’t tied to outcomes, they’re just added costs.
  • No transparency: Employers don’t know what portion of the cost is the drug vs. the markup.

How Leap does it better

Leap replaces the outdated pricing models with a pass-through pricing approach. That means employers pay only the actual cost of the drug—no markups, no hidden fees, no surprises.

Here’s how it works:

  1. True drug cost only: No inflated charges based on AWP or ASP
  2. Home-based administration: Avoids high-cost hospital settings altogether
  3. Transparent pricing and coordination: Reduces infusion costs by up to 50%
  4. Improved adherence: Easier access means fewer missed treatments and better outcomes

The bottom line

AWP, ASP, and WAC were never designed to serve employers - the ones who ultimately pay the bills. It’s time to move beyond legacy pricing systems that obscure costs and reward inefficiency. Leap offers a smarter solution that’s aligned with both cost savings and employee well-being.

Share this post

More insights

4fgyyvwF4RbiP1Ge Photo05%E2%80%94nursecheckingtheIVsite leap 05 nurse checking iv site 4962x2439 image
Infusion care

Is home infusion right for every patient? Here’s who decides

When patients learn they can receive their infusions at home, they might reasonably ask: Can I start...

Read article
uGsQNuRFuKAhTzKX benefits leader a reviewing report image
Education

Your guide to J-codes in medical billing, and what they can hide

An employer’s specialty trend was running at double digits, driven largely by therapies like Ocrevus...

Read article
gr 7yJaj1xLjiPDQ inside nurseadjustingIVdripforseniorpatientathome image
Education

Want to increase member participation in a specialty medicine solution? Reducing or waiving cost share is a good start.

One employee at a self-funded employer received Gammagard infusions twice a month for a rare autoimm...

Read article
A2LILi0roy6lnpj7 task export 6 image
Education

6 specialty medicine trends for 2027 and what they mean for benefits leaders

If it feels like specialty medicine is changing faster than your benefits strategy can keep up, that...

Read article
qmQqiddpjKSpw85s HRprofessional%E2%80%94intheoffice hr professional 3 office image
Education

Healthcare point solutions: What they are and 5 questions when evaluating them

If every healthcare point solution delivered the return in its sales deck, employer health costs wou...

Read article
XC0BuEWYGds6rfBI WeInfusepartnershipbloggraphic PNG%2C4962%C3%972439%2C300PPI 1 image
News

Leap expands specialty infusion network with WeInfuse collaboration

Leap is expanding its employer specialty infusion network through a new collaboration with WeInfuse,...

Read article
mIVvKbrIeVcspajE Spring Fall couplesittingtogetherongardenbenchwithcoffee image
Insights

Infusion vs. injection: Breaking down the basics of these two specialty therapies

In 1995, there were about 30 specialty drugs on the market. Today, there are nearly 1,000, and rough...

Read article
EJGfZMLy5m1bnieu inside closeupivdripformingdropletinhospital image
Insights

Let's blow up the buy-and-bill drug model: How it works and what it costs employers

Twice a year, a member with multiple sclerosis (MS) sits down for an Ocrevus infusion. The drug is t...

Read article
aVrzVnNYClf9oxJK Leap MS image
Insights

The real cost of MS infusion therapy and how a better member experience can bring down costs

For two years, Maria drove two hours each way for her multiple sclerosis (MS) treatment. Every appoi...

Read article
Oncology biosimilars market
Education

The emerging oncology biosimilars market and how employers can prepare.

A member who starts Keytruda today will likely organize the next two years of their life around it. ...

Read article